Patent ID: 7625937
Filing Date: 2009-12-01
Classification: A61P,C07D

Abstract:
1. A compound represented by Formula I or a pharmaceutically acceptable salt thereof, wherein: n is 0; J is NR K is NR L is C(R X is a bond, —C(O)—, —N(R R (1) C (2) C (3) C (4) C (5) C (6) C (7) aryl, (8) aralkyl, (9) HET, (10) —C (11) aryloxy, (12) aroyloxy, (13) aralkenyl, (14) aralkynyl, (15) hydrogen, (16) hydroxy and (17) C wherein items (1) to (6) above and the alkyl portions of items (8), (10) and (17) above and the alkenyl portion of item (13) above and the alkynyl portion of item (14) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR 13 , N(R 14 ) 2 , C 3-6 cycloalkyl and C 1-6 alkyl-S(O) k —, wherein k is 0, 1 or 2, and wherein items (7), (9), (11) and (12) above and aryl portion of items (8), (13) and (14) above and the HET portion of item (10) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: (a) halo, (b) OR (c) N(R (d) C (e) C (f) C (g) C (h) aryl, (i) aryl-S(O) j) HET, (k) aralkyl, (l) aroyl, (m) aryloxy, (n) aralkoxy and (o) CN, wherein items (d) to (g) above and the alkyl portions of item (k) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR 13 and N(R 14 ) 2 , and wherein items (h), (i), (j), (l) and (m) above and the aryl portions of items (k) and (n) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR 13 and C 1-4 alkyl, or when X is a bond then R 8 and R 10 may be joined together to form a 4- to 8-membered monocylic ring, optionally containing 1-3 heteroatoms selected from O, S and N, and optionally containing 1 or 2 double bonds; R (1) hydrogen, (2) halo, (3) C (4) C (5) C (6) C (7) C (8) C (9) aryl, (10) aralkyl, (11) HET and (12) —C wherein items (3) to (8) above and the alkyl portions of items (10) and (12) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR 13 , N(R 14 ) 2 and C 1-6 alkyl-S(O) k —, wherein k is 0, 1 or 2; and wherein items (9) and (11) and the aryl portion of items (10) and the HET portion of item (12) are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: (a) halo, (b) OR (c) N(R (d) C (e) C (f) C (g) C wherein items (d) to (g) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR 13 and N(R 14 ) 2 , or R 1 and R 3 or R 3 and R 5 may be joined together to form a double bond; R (1) hydrogen, (2) OR (3) C (4) aryl and (5) aralkyl, wherein item (3) above and the alkyl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR 13 and N(R 14 ) 2 , and wherein item (4) above and the aryl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: (a) halo, (b) OR (c) N(R (d) C (e) C (f) C wherein items (d) to (f) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR 13 and N(R 14 ) 2 ; Y is selected from the group consisting of: (1) hydrogen, (2) —O—R (3) —S(O) (4) —C—W—R (5) —N(R (6) —S(O) (7) —N(R (8) NO (9) —C(O)—R (10) —C(O)O—R (11) —CN, (12) halo and (13) —O—S(O) R each R (1) halo, (2) C (3) C (4) C (5) hydroxy, wherein items (2) to (4) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR 12 , N(R 13 ) 2 and C 1-6 alkyl-S(O) k —, wherein k is 0, 1 or 2; each R each R HET is a 5- to 10-membered aromatic, partially aromatic or non-aromatic mono- or bicyclic ring, containing 1-4 heteroatoms selected from O, S and N, and optionally substituted with 1-2 oxo groups.